English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/164876
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Gallic acid sensitizes paclitaxel-resistant human ovarian carcinoma cells through an increase in reactive oxygen species and subsequent downregulation of ERK activation

AuthorsSánchez-Carranza, Jessica Nayelli; Díaz, José Fernando ; Redondo-Horcajo, Mariano ; Barasoain, Isabel ; Álvarez, Laura ; Lastres, Pedro ; Romero, Antonio ; Aller, Patricio ; González-Maya, Leticia
Gallic acid
Reactive oxygen species
Ovarian cancer cells
Issue Date18-Apr-2018
PublisherSpandidos Publications
CitationOncol Rep 39(6):3007-3014 (2018)
AbstractPaclitaxel (PTX) is currently used as a front-line chemotherapeutic agent for several types of cancer, including ovarian carcinoma; however, PTX-resistance frequently arises through multiple mechanisms. The development of new strategies using natural compounds and PTX in combination has been the aim of several prior studies, in order to enhance the efficacy of chemotherapy. In this study, we found the following: (i) gallic acid (GA), a phenolic compound, potentiated the capacity of PTX to decrease proliferation and to cause G2/M cycle arrest in the PTX-resistant A2780AD ovarian cancer cell line; (ii) GA exerted a pro-oxidant action by increasing the production of reactive oxygen species (ROS), and co-treatment with the antioxidant agent N‑acetyl-L‑cysteine (NAC) prevented GA+PTX-induced cell proliferation inhibition and G2/M phase arrest; (iii) PTX stimulated ERK phosphorylation/activation, and co-treatment with the MEK/ERK inhibitor PD98049 potentiated the proliferation inhibition and G2/M phase arrest; (iv) and finally, GA abrogated the PTX-induced stimulation of ERK phosphorylation, a response that was prevented by co-treatment with NAC. Taken together, these results indicate that GA sensitizes PTX-resistant ovarian carcinoma cells via the ROS‑mediated inactivation of ERK, and suggest that GA could represent a useful co-adjuvant to PTX in ovarian carcinoma treatment.
Description8 p.-6 fig.
Publisher version (URL)https://doi.org/10.3892/or.2018.6382
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
Oncology Reports.2018_Sánchez-Carranza.pdfArtículo principal672,83 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.